1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor ID 6493

Awaiting development [GID-TA11639] Expected publication date: TBC

  • Project information
  • Project documents

35363-Pirtobrutinib-for-Mantle-Cell-Lymphoma-V1.0-JUL2024-NON-CONF.pdf (nihr.ac.uk)